Key result
Apixaban reduces bleeding events versus warfarin in dialysis patients while maintaining efficacy.
Why the study?
Does apixaban reduce bleeding events compared to warfarin in patients with ESRD maintained on dialysis?
Does apixaban reduce bleeding events compared to warfarin in patients with ESRD maintained on dialysis?
Apixaban may be a safer alternative to warfarin with fewer bleeding events in ESRD patients on dialysis.
No takes yet. Share an insight, caveat, or question.
May support apixaban preference in ESRD dialysis; hypothesis-generating and should not yet change practice.
Reed et al. (2018) studied this question. Apixaban is a safe and effective alternative to warfarin in patients with end-stage renal disease on dialysis, resulting in fewer bleeding events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: